Cannabis Bioscience Expands Research into Endocannabinoid Science

Cannabis Bioscience International Holdings, Inc. (CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, has announced an expanded research strategy aimed at exploring the intersection of endocannabinoid science and biological medicine. This strategic move comes as the company seeks to leverage the potential of cannabinoids and the endocannabinoid system in treating a wide range of complex diseases.

According to Dr. Rosangel Andrades, M.D., CBIH’s Director of Research and Development, the company is entering a new era in medicine where human biology plays a central role in the healing process.

CBIH plans to investigate the interaction between cannabinoids and the endocannabinoid system with molecular and cellular pathways associated with immune regulation, neuroinflammation, reproductive health, chronic pain, metabolic dysfunction, autoimmune diseases, cancer biology, and aging. The company emphasized that any therapeutic applications arising from these investigations would remain subject to scientific assessment, clinical validation, and applicable regulatory requirements.

To advance its long-term strategy, CBIH continues to prepare scientific studies to develop potentially patentable technologies and strengthen its intellectual property portfolio. The company is also anticipating the proposed broader federal rescheduling of marijuana from Schedule I to Schedule III, which it believes could open new research opportunities, strategic partnerships, and licensing agreements with medical, pharmaceutical, and biotechnology organizations. These initiatives are expected to drive future commercialization and long-term shareholder value, subject to research outcomes, regulatory requirements, and successful commercial agreements.

CBIH’s expansion into this new research area underscores its commitment to advancing the field of biological medicine and exploring the potential of cannabinoids in treating a wide range of diseases. The company’s efforts are part of a broader trend in the industry, where the focus is shifting from traditional treatments to more personalized and precise therapeutic strategies guided by each patient’s individual biology.